Blockchain Registration Transaction Record

GeoVax Completes Key Manufacturing Step for Next-Gen Mpox Vaccine

GeoVax Labs completes fill-finish for GEO-MVA Mpox/smallpox vaccine, advancing toward Phase 3 trials in 2026. This milestone strengthens U.S. pandemic preparedness by diversifying vaccine supply.

This development addresses critical vulnerabilities in global health security by moving toward a domestically produced alternative to the sole foreign supplier of MVA-based vaccines. With Mpox outbreaks expanding in Africa and emerging in the U.S., reliance on a single source creates supply chain risks that could hinder rapid response during public health emergencies. A diversified vaccine supply enhances pandemic preparedness, ensures more stable access during crises, and strengthens national biodefense infrastructure. For the public, this means greater assurance that effective vaccines will be available when needed, reducing the threat of vaccine shortages during outbreaks. It also represents progress in biotechnology innovation that could have broader applications for other infectious diseases.